Serotonin depletion in the dorsal and ventral hippocampus: Effects on locomotor hyperactivity, prepulse inhibition and learning and memory

Neuropharmacology

Volumn 55, Issue 6, 2008, Pages 1048-1055

  Adams, Wendy ^a,b   Kusljic, Snezana ^a,b   van den Buuse, Maarten ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cognition; Hippocampus; Median raphe nucleus; Phencyclidine; Serotonin

Indexed keywords

5,7 DIHYDROXYTRYPTAMINE; AMPHETAMINE; DIZOCILPINE; PHENCYCLIDINE; SEROTONIN;

ARTICLE; DISEASE MODEL; DORSAL HIPPOCAMPUS; DORSAL RAPHE NUCLEUS; HIPPOCAMPUS; HYPERACTIVITY; LEARNING; LOCOMOTION; MAZE TEST; MEDIAN RAPHE NUCLEUS; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SPATIAL MEMORY; VENTRAL HIPPOCAMPUS; WORKING MEMORY;

5,7-DIHYDROXYTRYPTAMINE; ANIMALS; BEHAVIOR, ANIMAL; HIPPOCAMPUS; HYPERKINESIS; LEARNING; MEMORY; NEURAL INHIBITION; PHENCYCLIDINE; RATS; SEROTONIN; SEROTONIN AGENTS;

EID: 53449100011     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.06.035     Document Type: Article

References (97)

1. Adams W., Kusljic S., and van den Buuse M. The involvement of serotonin in the dorsal hippocampus in NMDA receptor antagonist-induced locomotor hyperactivity is specific to phencyclidine and not MK-801. Journal of Pharmacological Sciences 101 (2006) S138
2. Aghajanian G.K., and Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36 (1997) 589-599
3. Aghajanian G.K., and Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews 31 (2000) 302-312
4. Altman H.J., Normile H.J., Galloway M.P., Ramirez A., and Azmitia E.C. Enhanced spatial discrimination learning in rats following 5,7-DHT-induced serotonergic deafferentation of the hippocampus. Brain Research 518 (1990) 61-66
5. Alves Fda S., Figee M., Vamelsvoort T., Veltman D., and Haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacology Bulletin 41 (2008) 121-132
6. 2C agonists into ventral but not dorsal hippocampus. Psychopharmacology 15 (2005) 37-43
7. Aparicio-Legarza M.I., Davis B., Hutson P.H., and Reynolds G.P. Increased density of glutamate/N-methyl-d-aspartate receptors in putamen from schizophrenic patients. Neuroscience Letters 241 (1998) 143-146
8. Bannerman D.M., Grubb M., Deacon R.M., Yee B.K., Feldon J., and Rawlins J.N. Ventral hippocampal lesions affect anxiety but not spatial learning. Behavioural Brain Research 139 (2003) 197-213
9. Bannerman D.M., Rawlins J.N., McHugh S.B., Deacon R.M., Yee B.K., Bast T., Zhang W.N., Pothuizen H.H., and Feldon J. Regional dissociations within the hippocampus-memory and anxiety. Neuroscience and Biobehavioral Reviews 28 (2004) 273-283
10. Baumgarten H.G., Klemm H.P., Sievers J., and Schlossberger H.G. Dihyodroxytryptamines as tools to study the neurobiology of serotonin. Brain Research Bulletin 9 (1982) 131-150
11. Breese G.R., Knapp D.J., and Moy S.S. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neuroscience and Biobehavioral Reviews 26 (2002) 441-445
12. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research 14 (1995) 187-202
13. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. British Journal of Psychiatry 174 (1999) 16-18
14. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 2569-2574
15. Buchanan R.W., Freedman R., Javitt D.C., Abi-Dargham A., and Lieberman J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophrenia Bulletin 33 (2007) 1120-1130
16. Bymaster F., Perry K.W., Nelson D.L., Wong D.T., Rasmussen K., Moore N.A., and Calligaro D.O. Olanzapine: a basic science update. British Journal of Psychiatry 174 (1999) 36-40
17. Cannon M., and Clarke M.C. Risk for schizophrenia - broadening the concepts, pushing back the bounderies. Schizophrenia Research 79 (2005) 5-13
18. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. A glutamatergic deficiency model of schizophrenia. British Journal of Psychiatry 174 (1999) 2-6
19. Carlsson A., and Lindqvist J. Effects of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 20 (1963) 140-144
20. Cassel J.C., and Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 69 (1995) 1-41
21. Choy K.H.C., de Visser Y., Nichols N.R., and van den Buuse M. Combined neonatal stress and young-adult glucocorticoid stimulation in rats reduces BDNF expression in hippocampus: effects on learning and memory. Hippocampus 18 (2008) 655-667
22. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 26 (2006) 365-384
23. de Bartolomeis A., Fiore G., and Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Current Pharmaceutical Design 11 (2005) 3561-3594
24. Dean B., and Hayes W. Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophrenia Research 21 (1996) 133-139
25. Degroot A., and Treit D. Anxiety is functionally segregated within the septo-hippocampal system. Brain Research 1001 (2004) 60-71
26. Dellu F., Mayo W., Cherkaoui J., Le Moal M., and Simon H. A two-trial memory task with automated recording: study in young and aged rats. Brain Research 588 (1992) 132-139
27. Drevets W.C., Gautier C., Price J.C., Kupfer D.J., Kinahan P.E., Grace A.A., Price J.L., and Mathis C.A. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry 49 (2001) 81-96
28. Fadda F., Cocco S., and Stancampiano R. Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats. Neuroreport 11 (2000) 2265-2269
29. Farber N.B. The NMDA receptor hypofunction model of psychosis. Annals of the New York Academy of Sciences 1003 (2003) 119-130
30. Galani R., Berthel M.C., Lazarus C., Majchrzak M., Barbelivien A., Kelche C., and Cassel J.C. The behavioral effects of enriched housing are not altered by serotonin depletion but enrichment alters hippocampal neurochemistry. Neurobiology of Learning and Memory 88 (2007) 1-10
31. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., and Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. American Journal of Psychiatry 157 (2000) 1141-1149
32. Garner B., Wood S.J., Pantelis C., and van den Buuse M. Early maternal deprivation reduces prepulse inhibition and impairs spatial learning ability in adulthood: no further effect of post-pubertal chronic corticosterone treatment. Behavioural Brain Research 176 (2006) 323-332
33. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36 (2000) 205-221
34. González-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., López-Giménez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., Gingrich J.A., Filizola M., Meana J.J., and Sealfon S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 (2008) 93-97
35. Gray J.A., and Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin 33 (2007) 1100-1119
36. Grimwood S., Slater P., Deakin J.F., and Hutson P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 10 (1999) 461-465
37. Guan X.M., and McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Research Bulletin 23 (1989) 541-547
38. Harder J.A., Kelly M.E., Cheng C.H., and Costall B. Combined pCPA and muscarinic antagonist treatment produces a deficit in rat water maze acquisition. Pharmacology, Biochemistry and Behavior 55 (1996) 61-65
39. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 (1999) 593-624
40. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sciences 48 (1991) 355-363
41. Hellweg R., Thomas H., Arnswald A., von Richthofen S., Kay S., Fink H., Morgenstern R., and Hortnagl H. Serotonergic lesion of median raphe nucleus alters nerve growth factor content and vulnerability of cholinergic septohippocampal neurons in rat. Brain Research 907 (2001) 100-108
42. Hietala J., and Syvalahti E. Dopamine in schizophrenia. Annals of Medicine 28 (1996) 557-561
43. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
44. Jonsson G. Chemical neurotoxins as denervation tools in neurobiology. Annual Reviews in Neuroscience 3 (1980) 169-187
45. Kahn R.S., and Davis K.L. New Developments in Dopamine and Schizophrenia. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 1193-1203
46. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (2004) 1081-1090
47. Kapur S., Mizrahi R., and Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 79 (2005) 59-68
48. Kerwin R., Patel S., and Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain postmortem. Neuroscience 39 (1990) 25-32
49. Kerwin R.W. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. British Journal of Psychiatry 164 (1994) 141-148
50. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. Journal of Neural Transmission 77 (1989) 231-236
51. Kusljic S., Brosda J., Norman T.R., and van den Buuse M. Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats. Brain Research 1049 (2005) 217-226
52. Kusljic S., Brosda J., and van den Buuse M. Effects of haloperidol and clozapine on sensorimotor deficits induced by 5-hydroxytryptamine depletion in the brain. British Journal of Pharmacology 147 (2006) 800-807
53. Kusljic S., Copolov D.L., and van den Buuse M. Differential role of serotonergic projections arising from the dorsal and median raphe nuclei in locomotor hyperactivity and prepulse inhibition. Neuropsychopharmacology 28 (2003) 2138-2147
54. Kusljic S., and van den Buuse M. Functional dissociation between serotonergic pathways in dorsal and ventral hippocampus in psychotomimetic drug-induced locomotor hyperactivity and prepulse inhibition in rats. European Journal of Neuroscience 20 (2004) 3424-3432
55. Kusljic S., and van den Buuse M. Differential involvement of 5-HT projections within the amygdala in prepulse inhibition but not in psychotomimetic drug-induced hyperlocomotion. Behavioural Brain Research 168 (2006) 74-82
56. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 9235-9240
57. Lehmann O., Bertrand F., Jeltsch H., Morer M., Lazarus C., Will B., and Cassel J.C. 5,7-DHT-induced hippocampal 5-HT depletion attenuates behavioural deficits produced by 192 IgG-saporin lesions of septal cholinergic neurons in the rat. European Journal of Neuroscience 15 (2002) 1991-2006
58. Lehmann O., Jeltsch H., Lazarus C., Tritschler L., Bertrand F., and Cassel J.C. Combined 192 IgG-saporin and 5,7-dihydroxytryptamine lesions in the male rat brain. A neurochemical and behavioral study. Pharmacology, Biochemistry and Behavior 72 (2002) 899-912
59. Lehmann O., Jeltsch H., Lehnardt O., Pain L., Lazarus C., and Cassel J.C. Combined lesions of cholinergic and serotonergic neurons in the rat brain using 192 IgG-saporin and 5,7-dihydroxytryptamine: neurochemical and behavioural characterization. European Journal of Neuroscience 12 (2000) 67-79
60. Luellen B.A., Szapacs M.E., Materese C.K., and Andrews A.M. The neurotoxin 2′-NH2-MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF. Neuropharmacology 50 (2006) 297-308
61. Majlessi N., Kadkhodaee M., Parviz M., and Naghdi N. Serotonin depletion in rat hippocampus attenuates L-NAME-induced spatial learning deficits. Brain Research 963 (2003) 244-251
62. 2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neuroscience Letters 403 (2006) 256-260
63. 2A receptor antagonism is dependent on increased serotonergic tone. Journal of Neural Transmission 105 (1998) 365-396
64. Martin S., and van den Buuse M. Phencyclidine-induced locomotor hyperactivity is enhanced in mice after stereotaxic brain serotonin depletion. Behavioural Brain Research 191 (2008) 289-293
65. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (2003) 1159-1172
66. Meneses A. 5-HT system and cognition. Neuroscience and Biobehavioral Reviews 23 (1999) 1111-1125
67. Meneses A. Do serotonin(1-7) receptors modulate short and long-term memory?. Neurobiology of Learning and Memory 87 (2007) 561-572
68. Mita T., Hanada S., Nishino N., Kuno T., Nakai H., Yamadori T., Mizoi Y., and Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biological Psychiatry 21 (1986) 1407-1414
69. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., and Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor ε{lunate}1 subunit. Journal of Neuroscience 21 (2001) 750-757
70. Moran P.M. Differential effects of scopolamine and mecamylamine on working and reference memory in the rat. Pharmacology, Biochemistry and Behavior 45 (1993) 533-538
71. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Current Opinion in Pharmacology 5 (2005) 101-106
72. Moser M., and Moser E. Functional differentiation in the hippocampus. Hippocampus 8 (1998) 608-619
73. Nilsson O.G., Strecker R.E., Daszuta A., and Bjorklund A. Combined cholinergic and serotonergic denervation of the forebrain produces severe deficits in a spatial learning task in the rat. Brain Research 453 (1988) 235-246
74. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neuroscience Letters 40 (1983) 245-250
75. Noga J.T., Hyde T.M., Herman M.M., Spurney C.F., Bigelow L.B., Weinberger D.R., and Kleinman J.E. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 27 (1997) 168-176
76. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., and Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 72 (2004) 29-39
77. 2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 (2002) 311-324
78. Rex A., Voigt J.P., and Fink H. Anxiety but not arousal increases 5-hydroxytryptamine release in the rat ventral hippocampus in vivo. European Journal of Neuroscience 22 (2005) 1185-1189
79. Richter-Levin G., and Segal M. Spatial performance is severely impaired in rats with combined reduction of serotonergic and cholinergic transmission. Brain Research 477 (1989) 404-407
80. Richter-Levin G., and Segal M. The effects of serotonin depletion and raphe grafts on hippocampal electrophysiology and behavior. Journal of Neuroscience 11 (1991) 1585-1596
81. Romano A.G., Quinn J.L., Liu R., Dave K.D., Schwab D., Alexander G., Aloyo V.J., and Harvey J.A. Effect of serotonin depletion on 5-HT2A-mediated learning in the rabbit: evidence for constitutive activity of the 5-HT2A receptor in vivo. Psychopharmacology (Berl) 184 (2006) 173-181
82. Roth B.L., and Meltzer H.Y. The Role of Serotonin in Schizophrenia. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 1215-1227
83. Schmitt J.A., Wingen M., Ramaekers J.G., Evers E.A., and Riedel W.J. Serotonin and human cognitive performance. Current Pharmaceutical Design 12 (2006) 2473-2486
84. Seeman P. Therapeutic receptor-blocking concentrations of neuroleptics. International Clinical Psychopharmacology 10 (1995) 5-13
85. Stancampiano R., Cocco S., Cugusi C., Sarais L., and Fadda F. Serotonin and acetylcholine release response in the rat hippocampus during a spatial memory task. Neuroscience 89 (1999) 1135-1143
86. Stancampiano R., Cocco S., Melis F., Cugusi C., Sarais L., and Fadda F. The decrease of serotonin release induced by a tryptophan-free amino acid diet does not affect spatial and passive avoidance learning. Brain Research 762 (1997) 269-274
87. Steckler T., and Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behavioural Brain Research 67 (1995) 165-199
88. 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Research 708 (1996) 209-214
89. Szapacs M.E., Numis A.L., and Andrews A.M. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiology of Disease 16 (2004) 572-580
90. Tamminga C. Glutamatergic aspects of schizophrenia. British Journal of Psychiatry 174 (1999) 12-15
91. Ueda S., Sakakibara S., and Yoshimoto K. Effect of long-lasting serotonin depletion on environmental enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neuroscience 135 (2005) 395-402
92. van den Buuse M., and Adams W. Modulation of the action of psychostimulant drugs of abuse by serotonin in the hippocampus: implcations for psychosis. Autralian and New Zealand Journal of Psychiatry 41 (2007) A462-A463
93. van den Buuse M., Garner B., Gogos A., and Kusljic S. Importance of animal models in schizophrenia research. Autralian and New Zealand Journal of Psychiatry 39 (2005) 550-557
94. Volpe B.T., Hendrix C.S., Park D.H., Towle A.C., and Davis H.P. Early post-natal administration of 5,7-dihydroxytryptamine destroys 5-HT neurons but does not affect spatial memory. Brain Research 589 (1992) 262-267
95. Wang R.Y., and Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19 (1998) 74-85
96. Wedzony K., Mackowiak M., Zajaczkowski W., Fijal K., Chocyk A., and Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23 (2000) 547-559
97. Whitton P.S., Richards D.A., Biggs C.S., and Fowler L.J. N-methyl-d-aspartate receptors modulate extracellular 5-hydroxytryptamine concentration in rat hippocampus and striatum in vivo. Neuroscience Letters 169 (1994) 215-218